
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1027 | 1027 | 965 | 1081 | 1411 | 1538 |
Fund Return | 2.71% | 2.71% | -3.52% | 2.62% | 7.12% | 4.4% |
Place in category | 18 | 18 | 350 | 136 | 267 | 159 |
% in Category | 3 | 3 | 42 | 22 | 54 | 61 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Seligson Co Global Top 25 Brands Fu | 754.99M | -8.41 | 3.45 | 8.96 | ||
Seligson & Co Global Top 25 Brands | 754.99M | -5.45 | 4.55 | 9.27 | ||
Seligson & Co North American A | 588.99M | -9.12 | 9.73 | 11.96 | ||
Seligson North American B | 588.99M | -12.02 | 8.54 | 11.59 | ||
FI4000283031 | 385.74M | -10.29 | 11.73 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Danske Invest MediLife T | 429.95K | 6.85 | 0.97 | 8.90 | ||
Danske Invest MediLife K | 77.24M | 6.85 | 0.95 | 8.90 | ||
Seligson Global Top 25 Pharmac B | 265.3M | -0.28 | 1.61 | 4.12 | ||
LahiTapiola Hyvinvointi A | 127.22M | -0.76 | -1.45 | 5.03 | ||
LahiTapiola Hyvinvointi B | 127.22M | -3.76 | -2.45 | 4.71 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Roche Holding Participation | CH0012032048 | 7.38 | 243.80 | +0.33% | |
AstraZeneca | GB0009895292 | 7.18 | 10,008.0 | -0.10% | |
J&J | US4781601046 | 7.07 | 151.73 | +2.04% | |
Novartis | CH0012005267 | 6.94 | 86.09 | +1.63% | |
Merck&Co | US58933Y1055 | 5.63 | 79.18 | +2.10% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review